| Literature DB >> 8082675 |
Abstract
Duchenne muscular dystrophy (DMD) is a devastating neuromuscular disorder caused by mutations in the dystrophin gene. The lack of adequate therapy for this disease provides impetus for the development of gene therapy strategies. A recombinant dystrophin cDNA and animal models of the disease are available for this therapy development. Characterization of these reagents and current progress toward gene therapy for DMD will be described.Entities:
Mesh:
Substances:
Year: 1994 PMID: 8082675 DOI: 10.1159/000117035
Source DB: PubMed Journal: Eur Neurol ISSN: 0014-3022 Impact factor: 1.710